Fulcrum Therapeutics Files Q1 2025 10-Q
Ticker: FULC · Form: 10-Q · Filed: May 1, 2025 · CIK: 1680581
| Field | Detail |
|---|---|
| Company | Fulcrum Therapeutics, INC. (FULC) |
| Form Type | 10-Q |
| Filed Date | May 1, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financials, stock-options
TL;DR
Fulcrum Therapeutics filed its Q1 2025 10-Q. Stock and treasury security details inside.
AI Summary
Fulcrum Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company's fiscal year ends on December 31st. Key financial data points and disclosures related to stock options, restricted stock units, and fair value measurements of U.S. Treasury Securities are included in this filing.
Why It Matters
This filing provides investors with an update on Fulcrum Therapeutics' financial position and operational activities for the first quarter of 2025, including details on stock-based compensation and investments.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Fulcrum Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2025-03-31 — Reporting Period End Date (Indicates the end of the fiscal quarter for which the report is filed.)
- 2025-05-01 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations.)
Key Players & Entities
- Fulcrum Therapeutics, Inc. (company) — Filer of the 10-Q
- 20250331 (date) — End of reporting period
- 20250501 (date) — Filing date
- 26 LANDSDOWNE STREET, CAMBRIDGE, MA 02139 (address) — Company business and mailing address
- Myokardia Agreement (contract) — Mentioned in relation to clinical and regulatory milestones
FAQ
What is the primary business of Fulcrum Therapeutics, Inc.?
Fulcrum Therapeutics, Inc. is classified under Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is March 31, 2025.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on May 1, 2025.
What types of financial instruments or agreements are mentioned in the filing?
The filing mentions Unvested Restricted Stock Units, Employee Stock Options, U.S. Treasury Securities, and the Myokardia Agreement.
What is the company's fiscal year end date?
Fulcrum Therapeutics, Inc.'s fiscal year ends on December 31st.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 1, 2025 regarding Fulcrum Therapeutics, Inc. (FULC).